Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Īhead of this earnings release, the estimate revisions trend for Blueprint Medicines: mixed. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Įmpirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. While Blueprint Medicines has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.īlueprint Medicines shares have added about 0.5% since the beginning of the year versus the S&P 500's gain of 8%. The company has topped consensus revenue estimates three times over the last four quarters. This compares to year-ago revenues of $107.02 million. Over the last four quarters, the company has surpassed consensus EPS estimates two times.īlueprint Medicines, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $38.78 million for the quarter ended December 2022, surpassing the Zacks Consensus Estimate by 18.58%. A quarter ago, it was expected that this cancer drug developer would post a loss of $2.51 per share when it actually produced a loss of $2.23, delivering a surprise of 11.16%. This quarterly report represents an earnings surprise of 2.93%. These figures are adjusted for non-recurring items. This compares to loss of $0.99 per share a year ago. Blueprint Medicines ( BPMC Quick Quote BPMC - Free Report) came out with a quarterly loss of $2.65 per share versus the Zacks Consensus Estimate of a loss of $2.73.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |